Systemic Th17/IL-23 immunomodulation for skin & joint repair support
Stem cell therapy for psoriasis in Istanbul, Turkey
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your psoriasis history, skin involvement, and joint symptoms to design an individualized Wharton's jelly MSC and exosome protocol.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Psoriasis is far more than a surface skin concern — it is a chronic, systemic immune-mediated condition in which overactive dendritic cells and helper T-cells lock the epidermis and microvasculature into an accelerated cycle of inflammation. Instead of renewing smoothly over nearly a month, stimulated keratinocytes multiply in just a few days, piling up into thickened, inflamed, silvery plaques accompanied by persistent itching, skin cracking, nail changes, and in many patients, painful psoriatic joint and enthesis stiffness that affects sleep, confidence, and daily comfort.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated to calm this systemic immune engine and help repair both cutaneous and joint microenvironments. Administered systemically, WJ-MSCs release anti-inflammatory cytokines (such as IL-10 and TGF-beta modulators) that downregulate the hyperactive IL-23 / Th17 / IL-17 and TNF-alpha pathways, convert pro-inflammatory M1 dermal macrophages into reparative M2 phenotypes, and expand regulatory T-cells (Tregs) to restore immune tolerance. Simultaneously, nanoscale WJ-MSC exosomes deliver regulatory microRNAs and trophic growth factors to stressed epidermal keratinocytes, dilated dermal capillaries, and inflamed synovial/entheseal tissues — helping normalize epidermal turnover, soothe microvascular leakage, and restore healthier skin barrier integrity.
At our Istanbul clinic, Uzm. Dr. Cihan Bolat and our medical team review your dermatological history, PASI skin distribution, nail or joint symptoms, and inflammatory biomarkers to design an individualized WJ-MSC and exosome protocol alongside your dermatologist's care. Our goal is to support clearer, calmer skin, greater joint comfort, and improved systemic vitality.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
Psoriasis is fueled by a self-amplifying loop between dendritic cells, Th17 T-cells, dermal capillaries, and keratinocytes. Regenerative medicine is investigated to modulate these upstream inflammatory signals and help restore healthy epidermal and joint homeostasis.
What our protocol aims to support
- Modulating overactive Th17 & cytokine pathways: Supporting systemic immune equilibrium by helping downregulate the IL-23, IL-17, and TNF-alpha signals that drive continuous plaque renewal and skin irritation.
- Restoring skin barrier & epidermal homeostasis: Delivering paracrine factors and exosomal signaling molecules aimed at normalizing keratinocyte turnover and promoting healthier dermal microenvironment balance.
- Addressing psoriatic joint & enthesis comfort: Providing systemic anti-inflammatory and trophic support for patients who experience accompanying joint stiffness, enthesitis, nail changes, or inflammatory fatigue.
- Complementing your ongoing dermatology care: Your protocol in Istanbul is coordinated safely alongside the topical, phototherapy, or systemic treatments overseen by your dermatologist at home.
- 01
Cutaneous & systemic Th17 / IL-23 / TNF-alpha activation
In psoriasis, stressed skin cells and plasmacytoid dendritic cells release antimicrobial peptides and IL-23, driving naive T-cells into aggressive Th17 and Th1 phenotypes that pour IL-17, IL-22, and TNF-alpha into the dermis and bloodstream. This chronic cytokine elevation fuels both visible skin plaques and systemic cardiometabolic and fatigue burdens. Wharton's jelly MSCs counter this cascade by secreting IDO, PGE2, and IL-10, which dampen dendritic-cell maturation and rebalance the Th17/Treg ratio. By calming upstream immune activation, WJ-MSCs and exosomes help quiet the biological driver of plaque recurrence.
- 02
Keratinocyte hyperproliferation & skin barrier disruption
Under constant bombardment by IL-17 and IL-22, basal keratinocytes accelerate their mitotic cycle from 28 days down to 3–5 days, migrating to the surface before they can properly differentiate or form a cohesive lipid barrier. This results in raised, erythematous plaques covered in silvery scale that crack, itch, and lose moisture easily. Exosomes derived from WJ-MSCs deliver regulatory microRNAs and trophic proteins directly to epidermal keratinocytes, helping downregulate STAT3-driven hyperproliferation. This cellular support encourages smoother epidermal maturation, reduced scaling, and restoration of a resilient cutaneous barrier.
- 03
Dermal microvascular inflammation & capillary dilation
Beneath every psoriatic plaque lies a dense network of dilated, tortuous, and hyper-permeable dermal capillaries stimulated by excessive vascular endothelial growth factor (VEGF) and endothelial adhesion molecules. These leaky microvessels give plaques their deep redness and continuously funnel fresh leukocytes into the skin. WJ-MSCs and their exosomes modulate endothelial activation, reduce excessive leukocyte-adhesion signaling (ICAM-1/VCAM-1), and calm perivascular macrophage M1 inflammation. Stabilizing the dermal microvasculature helps reduce skin erythema, local heat, and inflammatory cell infiltration.
- 04
Psoriatic joint, tendon & enthesis involvement
In up to a third of patients, the same IL-23/IL-17 and TNF-alpha immune signals target the entheses (where tendons and ligaments attach to bone) and synovial joints, causing morning stiffness, dactylitis, nail pitting, and progressive joint discomfort. If unaddressed, chronic enthesitis and synovitis degrade periarticular cartilage and bone. Systemic WJ-MSCs and exosomes circulate to inflamed synovial and entheseal microenvironments, shifting local macrophages toward reparative M2 phenotypes and delivering chondro-protective trophic factors. This dual support helps ease joint stiffness and protect musculoskeletal mobility alongside skin recovery.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Interrupting the IL-23 / Th17 Inflammatory Loop
Psoriatic plaques and psoriatic arthritis are driven by a systemic immune cascade in which dermal dendritic cells release IL-23, activating Th17 cells to flood the skin and joints with IL-17A, IL-22, and TNF-alpha. These cytokines force epidermal keratinocytes into rapid hyperproliferation while triggering abnormal angiogenesis in the dermal papillae. Regenerative medicine is investigated because calming this upstream T-cell and dendritic-cell cross-talk addresses the biological root of plaque formation rather than just exfoliating surface scales. Quieting systemic inflammation also helps protect tendons, entheses, and joints from cumulative inflammatory wear.
How WJ-MSCs & Exosomes Repair Skin & Joint Tissues
Wharton's jelly-derived MSCs (WJ-MSCs) act as intelligent systemic immunomodulators that inhibit pathogenic Th17 differentiation, expand protective FoxP3+ regulatory T-cells (Tregs), and shift cutaneous macrophages from pro-inflammatory M1 to tissue-healing M2 states. In tandem, WJ-MSC-derived exosomes circulate as nanoscale vesicles rich in anti-inflammatory microRNAs (such as miR-146a and miR-125b) and trophic factors that penetrate the dermis and synovial tissues. Inside the skin, these signals calm keratinocyte NF-kappaB and STAT3 activation, stabilize leaky dermal microvessels, and support normal lipid-barrier maturation. Within affected joints and tendon insertions, they help soothe synovitis and support cartilage and entheseal comfort.
Personalized Dermatology & Joint Protocol in Istanbul
Because psoriasis ranges from localized stubborn plaques and scalp/nail involvement to widespread skin burden with psoriatic arthritis, every treatment plan at our clinic is individually tailored. Uzm. Dr. Cihan Bolat and our medical team evaluate your skin photographs, PASI history, joint symptoms, CRP/ESR levels, and current topical, phototherapy, or biologic regimen. We then design a customized GMP-certified WJ-MSC and exosome protocol with matched administration routes that works safely alongside your home dermatologist's care. Structured 1, 3, and 6-month follow-ups monitor your skin clarity, PASI trajectory, and joint mobility.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intravenous Wharton's Jelly MSC (WJ-MSC) Infusion
Intravenous infusion delivers GMP-certified Wharton's jelly mesenchymal stem cells systemically to address the root immune dysregulation shared by psoriatic skin and joints. By secreting immunomodulatory factors (IL-10, PGE2, TGF-beta modulators), WJ-MSCs suppress pathogenic Th17 and dendritic-cell overactivity, expand protective regulatory T-cells (Tregs), and convert pro-inflammatory M1 macrophages into reparative M2 macrophages. This systemic immune recalibration helps reduce the continuous cytokine drive behind epidermal hyperproliferation and dermal vascular congestion. It is particularly valuable when plaques cover multiple body regions or are accompanied by psoriatic joint stiffness.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Intravenous WJ-MSC-Derived Exosome Administration
WJ-MSC-derived exosomes are nanoscale extracellular vesicles that circulate freely through dermal capillary beds and synovial tissues, carrying concentrated anti-inflammatory microRNAs, antioxidant enzymes, and trophic proteins. Taken up by epidermal keratinocytes and dermal endothelial cells, exosomes help quiet STAT3 and NF-kappaB signaling, calm itching and erythema, and support normal barrier keratinization alongside WJ-MSC therapy. They also deliver chondro-supportive and anti-inflammatory signals to tender entheses and joints. We note transparently that while combined cellular and exosomal signaling is biologically complementary, whether combined MSC and exosome therapy outperforms single-modality treatment remains under clinical study.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Intramuscular Administration (When Included in Your Protocol)
In selected psoriasis protocols, our medical team includes intramuscular delivery to establish a sustained local paracrine depot within well-perfused muscle tissue. Because intravenously administered MSCs experience initial first-pass retention in the lungs, intramuscular placement allows cells to remain locally active over a longer window, steadily releasing immunomodulatory cytokines and trophic vesicles into the systemic circulation. This gradual 'depot effect' aims to prolong the calming signal on Th17/IL-23 pathways and support smoother skin turnover between follow-up milestones. We distinguish this biological depot rationale from established clinical trial proof of pharmacokinetic superiority.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
Plaque Clearance & PASI Score Reduction
By calming IL-17/IL-23 signaling and normalizing keratinocyte turnover, our protocol aims to reduce plaque thickness, silvery scaling, and affected body surface area tracked via standardized PASI assessments.
- 02
Soothing Skin Redness, Itching & Barrier Comfort
Stabilizing dermal microvascular inflammation and supporting epidermal lipid-barrier repair helps ease persistent pruritus (itching), burning, and painful skin cracking so you can sleep and dress comfortably.
- 03
Psoriatic Joint, Nail & Enthesis Mobility
Systemic M1-to-M2 macrophage polarization and trophic exosome signaling help ease morning joint stiffness, tendon-insertion tenderness, and nail-bed inflammation for smoother daily movement.
- 04
Systemic Vitality & Emotional Wellbeing
Lowering chronic systemic cytokine activity (CRP, ESR) and improving visible skin comfort supports higher Dermatology Life Quality Index (DLQI) scores, deeper energy, and renewed social confidence.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat evaluates your psoriasis history, skin involvement, and joint symptoms to design an individualized Wharton's jelly MSC and exosome protocol.
Medical history & reports we request
- Confirmed psoriasis diagnosis, clinical subtype, and duration of symptoms
- Clear photographs of affected skin areas, scalp, or nails and prior PASI scores
- History of any joint pain, morning stiffness, or psoriatic arthritis diagnosis
- Recent blood tests including CBC, liver and kidney function, CRP, and ESR
- List of current and previous topical, phototherapy, oral, or biologic treatments
Clinical suitability & protocol checks
- Patients should continue their dermatologist-prescribed topical or systemic regimen unless their prescribing specialist advises an adjustment.
- Acute generalized pustular flares, erythroderma, or active skin infections require immediate local dermatological stabilization before travel.
- Our medical team tracks your skin and joint progress through structured photo and biomarker check-ins at 1, 3, and 6 months after your Istanbul visit.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- Patients should continue their dermatologist-prescribed topical or systemic regimen unless their prescribing specialist advises an adjustment.
- Acute generalized pustular flares, erythroderma, or active skin infections require immediate local dermatological stabilization before travel.
- Our medical team tracks your skin and joint progress through structured photo and biomarker check-ins at 1, 3, and 6 months after your Istanbul visit.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 Clinical guidelines and translational MSC research in psoriasis
Open study- Product
- Umbilical cord and Wharton's jelly mesenchymal stromal cells and exosomes
- Route
- Intravenous systemic immunomodulatory infusion
- Study design
- Consensus clinical practice guidelines and early-phase human MSC studies
- Finding
- Early clinical series and translational studies report encouraging immunomodulatory signals and PASI score improvements following allogeneic umbilical cord / Wharton's jelly MSC infusions.
- Limitation
- Controlled trials remain limited in size, and regenerative protocols are offered as supportive immunomodulation alongside established dermatological care.
Scientific references
Clinical studies and scientific references
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.